WEP CLINICAL ANNOUNCES PARTNERSHIP WITH PHARMING GROUP FOR EXPANDED ACCESS PROGRAM FOR LENIOLISIB
WEP Clinical (WEP) is pleased to announce our partnership [...]
WEP CLINICAL PARTNERS WITH SELLAS LIFE SCIENCES GROUP TO LAUNCH EXPANDED ACCESS PROGRAM FOR GALINPEPIMUT-S
WEP Clinical Inc. (WEP) is pleased to announce that [...]
WEP CLINICAL APPOINTS KARL CHALLENDER AS CHIEF OPERATING OFFICER
WEP Clinical (WEP), a specialist services company that works [...]
WEP CLINICAL ANNOUNCES PARTNERSHIP WITH HORIZON THERAPEUTICS FOR NAMED PATIENT USE PROGRAM FOR UPLIZNA
WEP Clinical (WEP) today announced a partnership with Horizon [...]
WEP CLINICAL ANNOUNCES NEW INVESTMENT MADE BY THE JORDAN COMPANY
WEP Group Holdings Limited (WEP Clinical) is pleased to [...]
WEP CLINICAL PARTNERS WITH KINIKSA TO LAUNCH ARCALYST NAMED PATIENT PROGRAM
WEP Clinical LTD (WEP), a specialist services company that [...]
WEP CLINICAL EXECUTES MASTER SERVICES AGREEMENT WITH MEDLAB TO BRING NANABIS™ AND NANOCBD™ TO PATIENTS IN UK AND EUROPE VIA ETHICAL NAMED PATIENT PROGRAMMES
WEP Clinical Ltd (WEP), a specialist services company that [...]
WEP CLINICAL ANNOUNCES PARTNERSHIP WITH HORIZON THERAPEUTICS PLC TO LAUNCH NAMED PATIENT USE PROGRAM FOR TEPEZZA® (TEPROTUMUMAB-TRBW)
WEP Clinical today announced a partnership with Horizon Therapeutics [...]
WEP CLINICAL EXPANDS AVAILABILITY OF XENLETA® (LEFAMULIN) NAMED PATIENT PROGRAM IN PARTNERSHIP WITH NABRIVA THERAPEUTICS
WEP Clinical (WEP) and Nabriva Therapeutics (Nabriva) are pleased [...]
WEP CLINICAL EXTENDS PARTNERSHIP WITH BTG SPECIALTY PHARMACEUTICALS BY GAINING WORLDWIDE (EX-US) DISTRIBUTION RIGHTS FOR DIGIFAB®
WEP Clinical (WEP) announced today that it has extended [...]